Tilray | TRLY - Current Assets

Stock Price
7.28
Daily Change
-0.26 -3.45%
Monthly
-22.22%
Yearly
970.59%
Q2 Forecast
7.47

Tilray reported $729.32M in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
Acasti Pharma USD 17.3M 3.22M Sep/2025
Akebia Therapeutics USD 243.48M 9.47M Mar/2026
Alaunos Therapeutics USD 970K 1.02M Mar/2026
Aurora Cannabis CAD 445.84M 22M Dec/2025
Avita Medical AUD 35.49M 760K Dec/2025
Canopy Growth CAD 524.67M 78.85M Dec/2025
Cronos Group USD 927.88M 16.21M Mar/2026
Dianthus Therapeutics USD 1.12B 710.47M Mar/2026
Divis Laboratories Ltd INR 98.43B 2.38B Sep/2025
Ionis Pharmaceuticals USD 2.94B 52M Mar/2026
IQVIA Holdings USD 6.22B 29M Mar/2026
Knight Therapeutics CAD 394.84M 5.86M Dec/2025
Moderna USD 5.77B 774M Mar/2026
Organigram Holdings CAD 256.54M 28.35M Dec/2025
Organon & Co USD 4.93B 580M Mar/2026
Revvity USD 2.13B 111.43M Mar/2026
Tectonic Therapeutic USD 239.89M 17.47M Mar/2026
Tilray USD 729.32M 28.18M Sep/2025
Viatris USD 10.92B 1.13B Mar/2026
Xeris Pharmaceuticals USD 251.68M 11.37M Mar/2026
Zealand Pharma A/S 15.67B 950.94M Dec/2025